Cellular and Molecular Research Center, Qazvin University of Medical Sciences, P.O. BOX: 59811-34197, Qazvin, Iran.
Department of Clinical Biochemistry, Faculty of Paramedicine, Ilam University of Medical Sciences, Ilam, Iran.
Neurochem Res. 2018 Dec;43(12):2313-2323. doi: 10.1007/s11064-018-2652-2. Epub 2018 Oct 4.
Parkinson's disease is the second most common neurodegenerative disease that occurs due to cellular autophagy deficiency and the accumulation of alpha-synuclein in the dopaminergic neurons of the substantia nigra pars compacta (SNc) of the brainstem. The SMER28 (also known as 6-Bromo-N-prop-2-enylquinazolin-4-amine) is an autophagy inducer. In this study, the neuroprotective effects of SMER28 were evaluated on autophagy induction, antioxidant system activation, and microgliosis attenuation. The Parkinson's disease model was developed in the male Wistar rats by injection of 6-OHDA into the left striatum. Apomorphine-induced behavior assessment test and SNc cell counting were performed to investigate the neuroprotective effects of SMER28. This study examined the pharmacological roles of SMER28, especially by focusing on the autophagy (p62/ SQSTM1 and LC3II/LC3I ratio where LC3 is microtubule-associated protein 1A/1B-light chain 3), inhibiting free radicals, and activating the antioxidant system. The levels of malondialdehyde (MDA), reactive oxygen species (ROS), glutathione (GSH), GSH/glutathione peroxidase (GP), superoxide dismutase (SOD) activity and nuclear factor-erythroid 2-related factor-2 (Nrf2) were measured to evaluate the antioxidant activity of SMER28. Moreover, Iba-1 (ionized calcium binding adaptor molecule, indicating microgliosis) and tyrosine hydroxylase immunoreactivities were evaluated in the SNc. In the behavioral assessment, SMER28 (50 µg/kg) attenuated damages to the SNc dopaminergic neurons, characterized by improved motor function. The tissue observations revealed that SMER28 prevented the destruction of SNc neurons and attenuated microgliosis as well. It also reduced MDA and ROS production and increased GSH, GP, SOD, and Nrf2 activities by inducing autophagy (decreasing p62 and increasing LC3II/LC3I ratio). Consequently, possibly with further studies, it can be considered as a drug for neurodegenerative diseases with proteinopathy etiology.
帕金森病是第二常见的神经退行性疾病,它是由于细胞自噬缺陷和脑干部位黑质致密部(SNc)中的多巴胺能神经元中α-突触核蛋白的积累引起的。SMER28(也称为 6-溴-N-丙-2-烯基喹唑啉-4-胺)是一种自噬诱导剂。在这项研究中,评估了 SMER28 对自噬诱导、抗氧化系统激活和小胶质细胞减少的神经保护作用。通过向左侧纹状体注射 6-OHDA 来开发雄性 Wistar 大鼠的帕金森病模型。进行阿扑吗啡诱导的行为评估测试和 SNc 细胞计数,以研究 SMER28 的神经保护作用。本研究检查了 SMER28 的药理学作用,特别是通过聚焦自噬(p62/SQSTM1 和 LC3II/LC3I 比值,其中 LC3 是微管相关蛋白 1A/1B-轻链 3)、抑制自由基和激活抗氧化系统。测量丙二醛(MDA)、活性氧(ROS)、谷胱甘肽(GSH)、GSH/谷胱甘肽过氧化物酶(GP)、超氧化物歧化酶(SOD)活性和核因子-红细胞 2 相关因子-2(Nrf2)的水平,以评估 SMER28 的抗氧化活性。此外,在 SNc 中评估了离子钙结合接头分子 1(Iba-1,表明小胶质细胞)和酪氨酸羟化酶免疫反应性。在行为评估中,SMER28(50μg/kg)减轻了对 SNc 多巴胺能神经元的损害,表现为运动功能改善。组织观察表明,SMER28 还可以防止 SNc 神经元的破坏和小胶质细胞的减少。它还通过诱导自噬(降低 p62 和增加 LC3II/LC3I 比值)来减少 MDA 和 ROS 的产生并增加 GSH、GP、SOD 和 Nrf2 的活性。因此,可能在进一步研究后,它可以被考虑作为一种治疗具有蛋白病病因的神经退行性疾病的药物。